Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | NR2F2 | P24468 | 5/20 | 0.63 |
| ▸ | ABL1 | P00519 | 5/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 5/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13467551 | 0.91 | NR2F2 (0.58) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL13467417 | 0.90 | NR2F2 (0.57) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL24600710 | 0.89 | ADORA3 (0.53) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL14047479 | 0.85 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL13467412 | 0.85 | NR2F2 (0.55) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL24600724 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL12566819 | 0.84 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL2036287 | 0.84 | ALDH1A1 (0.55) | ADORA3NR2F2ABL1RIN1 | |
| SCHEMBL29762643 | 0.84 | NT5E (0.52) | NPC1RAB9ASMN1; SMN2ADORA3NR2F2 | |
| SCHEMBL9589282 | 0.83 | ALDH1A1 (0.54) | ADORA3ABL1RIN1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | NPC1 4079/4885RAB9A 4290/4885SMN1; SMN2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.